Evonik raises methionine prices and unveils PFAS-free coating ahead of Q1 results
Evonik is set to release its first-quarter financial results on May 8
The company's stock saw a notable rise after geopolitical tensions in the Middle East disrupted methionine supply chains. In response, Evonik raised prices for its methionine product, MetAMINO®, by 10% worldwide. This increase is expected to improve profit margins in the animal nutrition division.
Evonik has also introduced a PFAS-free anti-graffiti coating, meeting stricter environmental rules. The move aligns with broader sustainability efforts as regulations tighten. For 2025, shareholders will receive a dividend of €1.00 per share. Starting in 2026, the payout ratio will shift to 40%–60% of adjusted net income. Despite this, the company's return on capital employed (ROCE) for 2025 stood at 6.1%, falling short of its mid-term goal of 11%. Looking forward, Evonik has maintained its 2026 EBITDA forecast at €1.7 to €2.0 billion. The upcoming quarterly report will provide further clarity on performance and strategy.
The price hike for methionine and the new anti-graffiti solution reflect Evonik's push to adapt to market and regulatory changes. With the first-quarter report due in May, investors will watch closely for updates on profitability and growth. The dividend policy adjustment and ongoing ROCE challenges will also remain key points of interest.
Read also:
- Federal Funding Supports Increase in Family Medicine Residency Program, Focusing on Rural Health Developments
- Potential Role of DHA in Shielding the Brain from Saturated Fats?
- Alternative Gentle Retinoid: Exploring Bakuchiol Salicylate for Sensitive Skin
- Hanoi initiates a trial program for rabies control, along with efforts to facilitate the transition from the dog and cat meat trade industry.
